Navigation Links
American Society for Microbiology honors Paul D. Bieniasz
Date:3/2/2010

The 2010 American Society for Microbiology (ASM) Eli Lilly and Company Research Award is being presented to Paul D. Bieniasz, Ph.D., Staff Investigator, Aaron Diamond AIDS Research Center, and Associate Professor and Head, Laboratory of Retrovirology, The Rockefeller University, New York, NY, and Investigator, Howard Hughes Medical Institute, for his work on retrovirus biology. This award recognizes fundamental research of unusual merit in microbiology or immunology by an individual on the threshold of his or her career.

Bieniasz received his Ph.D. from the Imperial College of Science, Technology, and Medicine, University of London, UK and completed his postdoctoral fellowship at Duke University, Durham, NC. He was recruited by the Aaron Diamond AIDS Research Center in 1999. His earlier work included the characterization of the TRIM5a restriction system in primate, rodent, and human cells, and its overlap with Cyclophilin A effects on virus replication. He also worked on the so-called L-domains and their interaction with the ESCRT system for enveloped virus budding, as well as the identification of the site and route of virus assembly and release at the cell surface. Bieniasz and colleagues generated a SHIV virus that replicates well in monkeys which is a major breakthrough that will facilitate study of vaccines and drugs in a primate model.

Bienasz's most recent and exciting work is his identification of the gene he calls "tetherin." A newly-identified antiviral molecule, tetherin is expressed on the surface of cells and blocks the release of freshly-assembled viral particles. This is a novel mechanism by which hosts can defend themselves against viruses. It appears that the tetherin protein is an active component of the interferon-induced innate immune response. It was known that the block was antagonized by Vpu. It was Bieniasz's dissection of how the absence of Vpu causes retention of new HIV-1 particles on the surface of interferon treated cells that lead to the discovery of tetherin.

The Eli Lilly and Company Research Award will be presented during the 110th General Meeting of the ASM, May 23-27, 2010 in San Diego, CA. ASM is the world's oldest and largest life science organization and has more than 43,000 members worldwide. ASM's mission is to advance the microbiological sciences and promote the use of scientific knowledge for improved health and economic and environmental well-being.


'/>"/>

Contact: Garth Hogan
ghogan@asmusa.org
American Society for Microbiology
Source:Eurekalert

Related biology news :

1. American Chemical Societys Weekly PressPac -- Aug. 8, 2007
2. Understanding hypertension in African Americans proves elusive
3. Tips from the Journals of the American Society for Microbiology
4. American Chemical Societys Weekly PressPac -- Aug. 15, 2007
5. American College of Medical Genetics responds to new FDA labeling decision for warfarin
6. American Chemical Societys Weekly Press Pac
7. Highlights from the September 2007 Journal of the American Dietetic Association
8. American Chemical Societys Weekly Presspac -- Aug. 29, 2007
9. Report: African, Asian, Latin American farm animals face extinction
10. American Chemical Society calls green chemistry bill a smart step
11. Challenges remain in reintroducing American chestnut
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a community ... that it has received Laboratory Accreditation from the ... is presented to laboratories that meet stringent requirements ... scientifically rigorous processes. "Genos is committed ... laboratory practices. We,re honored to be receiving CAP ...
(Date:2/14/2017)... , Feb. 14, 2017  Wake Forest Baptist ... as its new chief executive officer (CEO). Freischlag joins ... John D. McConnell , M.D., who last year ... at the Medical Center, after leading it since 2008. ... full scope of Wake Forest Baptist,s academic health system, ...
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- ... platform that is designed to enhance fraud detection ... release in the RSA Fraud & Risk Intelligence ... organizations to leverage additional insights from internal and ... to better protect their customers from targeted cybercrime ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... and GREENWICH, Conn. , Feb. ... firm focused on venture growth investments in biotechnology ... Josh Richardson , M.D. to Managing Director. ... biotechnology companies.  He is a board observer at ... in Longitude,s investments in Aimmune Therapeutics, Akebia Therapeutics, ...
(Date:2/16/2017)... CALABASAS, Calif. , Feb. 16, 2017 /PRNewswire/ ... on developing groundbreaking therapies to treat severe neurological ... in children treated with AGT-181, the company,s investigational ... syndrome (also known as mucopolysaccharidosis type I, or ... Phase 2 proof-of-concept (POC) study, presented today at ...
(Date:2/16/2017)... 2017   Capricor Therapeutics, Inc. (NASDAQ: ... developing first-in-class biological therapies for cardiac and other ... to terminate its license agreement with the Mayo ... Cenderitide. "Our decision to return these ... our efforts to advance our core cell and ...
(Date:2/16/2017)... , February 16, 2017 ... infusion of innovative telemedicine application, new and leading ... are experiencing a boom worldwide. The healthcare sector ... of technologies, services and new therapies for companies ... (TSX-V: RHT), Cellectar Biosciences, Inc. (NASDAQ: ...
Breaking Biology Technology: